Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 22OTHER 13NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Has results × binimetinib × Clear all
NCT04439344 2026-05-07

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
53 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡